Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus

Transfusion

Volumn 43, Issue 12, 2003, Pages 1667-1671

  Leitman, Susan F ^a   Tisdale, John F ^b   Bolan, Charles D ^b   Popovsky, Mark A ^b   Klippel, John H ^b   Balow, James E ^b   Boumpas, Dimitrios T ^b   Illei, Gabor G ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; THYMOCYTE ANTIBODY; TIOGUANINE; VINCRISTINE;

ADULT; ALLELE; ANEMIA; ARTICLE; BONE MARROW APLASIA; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CANDIDIASIS; CASE REPORT; DEATH; ERYTHROCYTE CONCENTRATE; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; LYMPHOMA; PANCYTOPENIA; RASH; RISK FACTOR; SKIN BIOPSY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE;

ADULT; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ERYTHROCYTE TRANSFUSION; FATAL OUTCOME; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLATELET TRANSFUSION; RISK FACTORS; VIDARABINE;

EID: 0344581059     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0041-1132.2003.00579.x     Document Type: Article

References (21)

1. Leitman SF. Use of blood cell irradiation in the prevention of posttransfusion graft-vs-host disease. Transfus Sci 1989;10:219-32.
2. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host-disease. N Engl J Med 1990;323:315-21.
3. Shivdasani RA, Anderson KC. The role of HLA homozygosity in the development of transfusion-associated graft-versus-host disease. Leuk Lymphoma 1994;15:227-34.
4. Davey RJ, McCoy NC, Yu M, et al. The effect of prestorage irradiation on posttransfusion red cell survival. Transfusion 1992;32:525-8.
5. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991;9:175-88.
6. Boldt DH, Von Hoff DD, Kuhn JG, Hersh M. Effects on human peripheral lymphocytes of in vivo administration of 9-β -D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984;44:4461-6.
7. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347:1432-8.
8. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695-700.
9. Boumpas DT, Tassiulas IO, Fleisher TA, et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol 1999;52:67-75.
10. Davis JC Jr, Fessler BJ, Tassiulas IO, et al. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. J Rheumatol 1998;25:1694-704.
11. Maung ZT, Wood AC, Jackson GH, et al. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukemia. Br J Haematol 1994;88:649-52.
12. Briz M, Cabrera R, Sanjuan I, et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukemia. Br J Haematol 1995;91:409-11.
13. Williamson LM, Wimperis JZ, Wood ME, Woodcock B. Fludarabine treatment and transfusion-associated graft-versus-host disease (letter). Lancet 1996;348:472-3.
14. Deane M, Gor D, Macmahon ME, et al. Quantification of CMV viremia in a case of transfusion-associated graft-versus-host disease associated with fludarabine treatment. Br J Haematol 1997;99:162-4.
15. Zelig O, Dacosta Y, Oz D, Mamen N. TA-GVHD following fludarabine treatment in a patient with NHL. Abstracts of the Sixth Regional European Congress of the International Society of Blood Transfusion, 9-13 May, 1999. Jerusalem, Israel, 1999:128a.
16. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993;50:292-6.
17. Davis JC, Tassiulas IO, McInnes IB, et al. Lymphocyte reconstitution after intravenous fludarabine in patients with rheumatoid arthritis (abstract). Arthritis Rheum 1998;41:S138.
18. Briones J, Pereira A, Alcorta I. Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component? Br J Haematol 1996;93:737-41.
19. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19:1414-20.
20. BCSH Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med 1996;6:261-71.
21. Zulian GB, Roux E, Tiercy JM, et al. Transfusion-associated graft-versus-host disease in a patient treated with cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br J Haematol 1995;89:83-9.